Cardiotec is a drug owned by Bracco Diagnostics Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 28, 2019. Details of Cardiotec's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6056941 | Kit for the preparation of technetium TC 99m teboroxime myocardial perfusion agent |
Jul, 2019
(5 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Cardiotec is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cardiotec's family patents as well as insights into ongoing legal events on those patents.
Cardiotec's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cardiotec's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 28, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cardiotec Generics:
There are no approved generic versions for Cardiotec as of now.
About Cardiotec
Cardiotec is a drug owned by Bracco Diagnostics Inc. Cardiotec uses Technetium Tc-99M Teboroxime Kit as an active ingredient. Cardiotec was launched by Bracco in 1990.
Approval Date:
Cardiotec was approved by FDA for market use on 19 December, 1990.
Active Ingredient:
Cardiotec uses Technetium Tc-99m Teboroxime Kit as the active ingredient. Check out other Drugs and Companies using Technetium Tc-99m Teboroxime Kit ingredient
Dosage:
Cardiotec is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| N/A | INJECTABLE | Discontinued | INJECTION |